Companies: 10,795·Total market cap: $144.5T
Eli Lilly and Company

Eli Lilly and Company

LLYNYSEHealthcare● Active
$1,131.42
+$6.15(+0.55%)
Market Cap$1.07T
P/E Ratio—
52W High$1166.29
52W Low$623.78
Overview

Eli Lilly and Company (LLY) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

LLY · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$7.27B▲ +112.3% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$7.16B
cashAndCashEquivalents
Short-Term Investments
$105.0M
shortTermInvestments
YoY Change vs Prior Year
+112.3%
vs prior fiscal year
Latest Quarter
$5.28B
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$7.27BCash on Hand
Total Debt$42.50BTotal Debt
Net Cash / Net Debt−$35.23BNet Debt Position
Cash vs Debt Ratio
Cash 15%Debt 85%

Eli Lilly and Company carries a net debt position of $35.23B. Total debt ($42.50B) exceeds cash on hand ($7.27B). Eli Lilly and Company cash vs debt ratio: 15% cash / 85% debt.

Net Cash = Cash & ST Investments − Total Debt$7.27B − $42.50B = −$35.23B

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
LLY annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$7.27B+112.3%
Dec 31, 2024$3.42B+16.9%
Dec 31, 2023$2.93B+32.4%
Dec 31, 2022$2.21B-43.4%
Dec 31, 2021$3.91B+6.2%
LLY cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.8%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Merck & Co., Inc.
Merck & Co., Inc.
MRK
$14.56B4.9%
#4
Eli Lilly and Company
Eli Lilly and CompanyYOU
LLY
$7.27B0.7%
#5
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Eli Lilly and Company (LLY) cash on hand as of December 31, 2025 is $7.27B, comprising $7.16B in cash and cash equivalents (CCE) plus $105.0M in short-term investments — reported as Eli Lilly and Company cash and short-term investments on the balance sheet (10-K filing). Also referred to as Eli Lilly and Company cash reserves or cash position.

Eli Lilly and Company annual cash on hand history shows increased +112.3% in 2025: increased +112.3% in 2025. Eli Lilly and Company cash reserves in 2025 reflect the company's capital allocation strategy.

Eli Lilly and Company carries total debt of $42.50B against cash of $7.27B, resulting in a net debt position of -$35.23B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

LLY cash on hand · 5 questions

As of December 31, 2025, Eli Lilly and Company (LLY) has $7.27B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $7.16B in cash and cash equivalents (CCE) plus $105,000,000 in short-term investments. Latest quarter (March 31, 2026): $5.28B. Data sourced from the annual 10-K filing via FMP.

LLY cash on handLLY cash reservesLLY cash 2025how much cash does LLY have

▸ Source: FMP /balance-sheet-statement · US GAAP · Eli Lilly and Company · Eli Lilly and Company SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025